2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Sialyltransferase

Sialyltransferase

Sialyltransferase

Sialyltransferases are enzymes that transfer sialic acid to nascent oligosaccharides. Sialyltransferases (SiaTs) exhibit distinct characteristics and preferences, such as for substrates and glycosidic linkages. Sialyltransferases use cytidine monophosphate N-acetylneuraminic acid (CMP-Neu5Ac) as an activated sugar donor. Overexpression of sialyltransferases is associated with tumor hypersialylation and poor outcome[1].

Sialyltransferase Related Products (15):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-110288
    3FAx-Neu5Ac
    		99.88%
    3FAx-Neu5Ac (Compound 8), a Sialic acid peracetylated analog, is a sialyltransferase inhibitor. 3FAx-Neu5Ac substantially reduces expression of the sialylated ligand sialyl Lewis X.
    3FAx-Neu5Ac
  • HY-112415
    Lith-O-Asp
    		98.0%
    Lith-O-Asp is a sialytransferase (ST) inhibitor, with IC50s of 12-37 μM.
    Lith-O-Asp
  • HY-E70024
    CMP-sialic acid synthetase (NmCSS)
    CMP-sialic acid synthetase (NmCSS) is an essential enzyme involved in the biosynthesis of carbohydrates and glycoconjugates containing sialic acids. CMP-sialic acid synthetase (NmCSS) activates free Sia, converting it to CMP-Sia, which is the only donor substrate for all sialyltransferases.
    CMP-sialic acid synthetase (NmCSS)
  • HY-E70056
    α2,3-Sialyltransferase, Pasteurella multocida (P-1059)
    α2,3-Sialyltransferase, Pasteurella multocida (P-1059) (PmST1(M144D)), a sialyltransferase, can be isolated from Pasteurella multocida. alpha-2,3-Sialyltransferase (PmST1) can be converted into regioselective α2-6-sialyltransferase by saturation mutagenesis and regioselective screening.
    α2,3-Sialyltransferase, Pasteurella multocida (P-1059)
  • HY-173496
    ST6GAL1-IN-1
    		Inhibitor 99.22%
    ST6GAL1-IN-1 is an orally active selective ST6GAL1 inhibitor (IC50 = 20 μM). ST6GAL1-IN-1 exhibits high antimetastatic potential, effectively inhibiting the migration of MDA-MB-231 cells at noncytotoxic concentrations. ST6GAL1-IN-1 can disrupt integrin sialylation in MDA-MB-231 cells. ST6GAL1-IN-1 inhibits tumor angiogenesis and cancer metastasis via the Integrin/VEGFR2-mediated signaling pathway. ST6GAL1-IN-1 effectively suppresses both tumor growth and cancer metastasis on the MDA-MB-231 xenograft model. ST6GAL1-IN-1 can be used for the study of Triple-negative breast cancer (TNBC).
    ST6GAL1-IN-1
  • HY-E70055
    α-2,6-Sialyltransferase, pasteurella multocida (P-1059)
    alpha-2,6-Sialyltransferase (Pd26ST) (EC 2.4.99.1) is capable of sialylating both terminal and internal galactose and N-acetylgalactosamine, which producing terminal α2,6-sialosides.
    α-2,6-Sialyltransferase, pasteurella multocida (P-1059)
  • HY-112535
    (R)-Lith-O-Asp
    		98.0%
    (R)-Lith-O-Asp (α-2,3-Sialyltransferase-IN-1) is a noncompetitive α-2,3-sialyltransferase inhibitor with an IC50 of 6 μM.
    (R)-Lith-O-Asp
  • HY-101218
    N-Biotinyl-6-aminohexanoic acid
    		99.84%
    N-Biotinyl-6-aminohexanoic acid (N-(+)-Biotinyl-6-aminohexanoic acid) can be used to perform biotinylation.
    N-Biotinyl-6-aminohexanoic acid
  • HY-E70065
    alpha-2,3-Sialyltransferase (PmST2)
    alpha-2,3-Sialyltransferase (PmST2) is a sialyltransferase produced by Pasteurella multocida (Pm) and plays an important role in the pathogenesis of Pm. alpha-2,3-Sialyltransferase (PmST2) can be used to synthesize sialyllactosyl sphingosine (lyso-GM3).
    alpha-2,3-Sialyltransferase (PmST2)
  • HY-163548
    SPP-002
    		Inhibitor 98.0%
    SPP-002 is a ST6GAL1 inhibitor with a human IC50 of 16.7 μM. SPP-002 selectively inhibits N-glycan sialylation over O-glycan sialylation and binds strongly to the enzyme active site. SPP-002 suppresses expression of signaling proteins in the integrin/FAK/paxillin pathway. SPP-002 can be used for the research of triple negative breast cancer metastasis.
    SPP-002
  • HY-112944A
    CMP-SiaNAz sodium
    		Substrate
    CMP-SiaNAz (CMP-NeuNAz) sodium is a sialic acid nucleotide sugar derivative. CMP-SiaNAz sodium is integrated into the glycosidic chain through the action of STs in the Golgi apparatus, forming SiaNAz substances. CMP-SiaNAz sodium can serve as a substrate for bacterial-derived sialic acid transferases and is used for chemical enzymatic labeling and imaging of cell surface glycosides.
    CMP-SiaNAz sodium
  • HY-179101
    IAN-15B
    		Inhibitor
    IAN-15B has high selectivity and potent ST6GAL1 inhibitors (IC50 = 3.3 μM). IAN-15B has significant anti migratory and anti angiogenic effects. IAN-15B can be used in the research of cancer such as breast cancer.
    IAN-15B
  • HY-172888
    SPP-037
    		Inhibitor
    SPP-037 is an orally active and selective inhibitor of ST6GAL1 (IC50 = 3.59 μM). SPP-037 inhibits integrin α2,6-sialylation and integrin-FAK-paxillin pathway. SPP-037 inhibits cancer cell proliferation, migration and exhibits antiangiogenic activity. SPP-037 has anti-tumor activity in MDA-MB-231 xenograft mouse model. SPP-037 can be used for the research of triple-negative breast cancer.
    SPP-037
  • HY-E70150
    ST6 Sialyltransferase 1
    ST6 Sialyltransferase 1 (EC:2.4.3.3, ST6GALNAC1, SIAT7A, Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1)? transfers a sialic acid, N-acetylneuraminic acid (NeuAc), in an alpha-2,6 linkage to O-linked GalNAc residues. ST6 Sialyltransferase 1 plays an important role in cancer.
    ST6 Sialyltransferase 1
  • HY-P991369
    EBU-141
    		Inhibitor
    EBU-141 is a human monoclonal antibody (mAb) targeting CD75/ST6GAL1. EBU-141 can be used in B-cell lymphoma and multiple myeloma research.
    EBU-141